Popular Weight Loss Drugs May Weaken Your Bones—Here's What Researchers Found

New research presented at the American Academy of Orthopedic Surgeons' annual meeting suggests that popular weight loss medications like Ozempic and Wegovy may come with an unexpected bone health cost. An analysis of medical records from over 146,000 adults with obesity and Type 2 diabetes found that people taking glucagon-like peptide-1 (GLP-1) drugs had significantly higher rates of osteoporosis, bone-softening conditions, and gout compared to those not taking the medications.

What Did the Research Actually Show?

Researchers compared patients taking GLP-1 drugs to those who weren't, examining five years of medical records. The findings were striking: about 4% of GLP-1 users developed osteoporosis, compared with just over 3% of non-users—representing a 30% increased risk. Even more concerning, osteomalacia, a condition that softens and weakens bones, occurred about twice as often among people on GLP-1s. Additionally, gout rates were 7.4% for GLP-1 users versus 6.6% for non-users, an increase of about 12%.

The study, led by Dr. John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania, was prompted by an unusual observation. "Dr. Horneff began looking into the issue after some patients appeared to develop serious tendon tears after relatively minor injuries," which led researchers to examine whether GLP-1s might affect bone and connective tissue more broadly.

Why Might Weight Loss Drugs Affect Your Bones?

Experts have identified several potential mechanisms linking GLP-1 drugs to bone loss. The most straightforward explanation involves nutrition: these medications suppress appetite, which means some patients may not consume enough key nutrients essential for bone health. "People are taking these medications, and obviously there's a tremendous amount of upside," Dr. Horneff explained. "But with that, they start to decrease their intake of food and nutrients".

Rapid weight loss itself may also trigger bone loss. When the body loses weight quickly, it may change how bones are built and broken down. Dr. Horneff used an analogy to explain this mechanism: "It's the same idea like when we always hear about astronauts going up into space and they're in a gravity-zero environment for too long. There's nothing forcing their bones to kind of hold their weight anymore. And a lot of those astronauts come back with low bone density. So the thought is, these patients, their skeleton was used to kind of maintaining one frame, and then all of a sudden, that's being decreased".

For gout specifically, rapid weight loss can cause a temporary spike in uric acid—a waste product created when the body breaks down chemicals called purines in food and drinks—which increases the risk of this painful form of arthritis.

Steps to Protect Your Bone Health While Taking GLP-1 Drugs

• Monitor Nutrient Intake: Ensure you're consuming adequate calcium and vitamin D, which are critical for maintaining bone density. Since GLP-1 drugs suppress appetite, you may need to be intentional about getting these nutrients through food or supplements.
• Maintain Regular Exercise: Research suggests that when GLP-1s are combined with structured exercise, bone density loss is largely mitigated. Weight-bearing and resistance exercises are particularly important for bone health.
• Get Bone Density Screening: If you're taking GLP-1 drugs, especially if you're over 50 or have risk factors for osteoporosis, discuss bone density screening with your doctor to catch any changes early.
• Work with Your Healthcare Team: Obesity treatment requires guidance on protein intake, exercise, and bone health monitoring. Don't rely on the medication alone—partner with your doctor on a comprehensive approach.

What About the Bigger Picture?

It's important to note that this research was observational, meaning scientists can't definitively prove that GLP-1 drugs caused these bone conditions. The study didn't include detailed information about patients' diet, exercise habits, or whether they were taking vitamin D supplements—all factors that could influence bone health. Additionally, the Food and Drug Administration already notes in its label for semaglutide (the active ingredient in Ozempic and Wegovy) that it might increase the risk of bone fractures in older adults and women.

Dr. Clifford Rosen, a professor of medicine at Tufts University who studies GLP-1 impacts on bone health, emphasized the complexity: "Weight loss does cause bone loss. The question we've been studying is whether this is a normal compensation of the skeleton, it's just reshaping itself, or whether this is truly a risk for losing bone that's more rapid than what would be expected".

The good news? Experts stress that these findings shouldn't cause panic. Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in North Carolina, put it plainly: "The takeaway isn't fear. It's refinement". This means that with proper monitoring, nutrition, and exercise, many of the bone health risks associated with GLP-1 drugs can be managed or prevented.

If you're considering or currently taking a GLP-1 weight loss drug, the key is to work closely with your healthcare provider to monitor your bone health, ensure adequate nutrient intake, and maintain an active lifestyle. These medications have proven benefits for weight loss and blood sugar control, but like all medications, they require informed use and ongoing health management.